Frontiers in Immunology (Jul 2021)

IRF7-Associated Immunophenotypes Have Dichotomous Responses to Virus/Allergen Coexposure and OM-85-Induced Reprogramming

  • Emma de Jong,
  • Emma de Jong,
  • Jean-Francois Lauzon-Joset,
  • Jean-Francois Lauzon-Joset,
  • Jonatan Leffler,
  • Jonatan Leffler,
  • Michael Serralha,
  • Alexander N. Larcombe,
  • Alexander N. Larcombe,
  • Claus T. Christophersen,
  • Claus T. Christophersen,
  • Patrick G. Holt,
  • Deborah H. Strickland,
  • Anthony Bosco,
  • Anthony Bosco

DOI
https://doi.org/10.3389/fimmu.2021.699633
Journal volume & issue
Vol. 12

Abstract

Read online

High risk for virus-induced asthma exacerbations in children is associated with an IRF7lo immunophenotype, but the underlying mechanisms are unclear. Here, we applied a Systems Biology approach to an animal model comprising rat strains manifesting high (BN) versus low susceptibility (PVG) to experimental asthma, induced by virus/allergen coexposure, to elucidate the mechanism(s)-of-action of the high-risk asthma immunophenotype. We also investigated potential risk mitigation via pretreatment with the immune training agent OM-85. Virus/allergen coexposure in low-risk PVG rats resulted in rapid and transient airways inflammation alongside IRF7 gene network formation. In contrast, responses in high-risk BN rats were characterized by severe airways eosinophilia and exaggerated proinflammatory responses that failed to resolve, and complete absence of IRF7 gene networks. OM-85 had more profound effects in high-risk BN rats, inducing immune-related gene expression changes in lung at baseline and reducing exaggerated airway inflammatory responses to virus/allergen coexposure. In low-risk PVG rats, OM-85 boosted IRF7 gene networks in the lung but did not alter baseline gene expression or cellular influx. Distinct IRF7-associated asthma risk immunophenotypes have dichotomous responses to virus/allergen coexposure and respond differentially to OM-85 pretreatment. Extrapolating to humans, our findings suggest that the beneficial effects OM-85 pretreatment may preferentially target those in high-risk subgroups.

Keywords